echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The Lancet: Antiviral "cocktail therapy" with interferon beta-1b is effective for patients with new crowns with mild secondary disease

    The Lancet: Antiviral "cocktail therapy" with interferon beta-1b is effective for patients with new crowns with mild secondary disease

    • Last Update: 2020-05-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    REVIEW: The latest study shows that interferon β-1b, lopinavir - ritonavir and ribavirin "triple therapy" effective and safe in the treatment of early COVID-19new crown pneumonia (COVID-19) development of the epidemic so far has resulted in nearly 400 million people infected worldwide, more than 27 million deathsCurrently, more than the world's research institutions and companies are working to find the cure for COVID-19, in which the fight against Ebola virus Orem Xi Wei, the treatment of malaria drug chloroquine and hydroxychloroquine, drug combinations against AIDS Kaletra ( ritonavir / lopinavir) and a combination of Kaletra and interferon β-1b, etc., previously thought to be a cure for the "star player."However, several studies from recently released reports, the antimalarial drug hydroxychloroquine and chloroquine side effects caused by arrhythmia patients may become "straw", Western Wei Reid does not seem to be "of the people I hope ", while Kaletra therapy with conventional treatment seems to be no differenceRecently, six public hospitals in Hong Kong by the Chinese as well Researchers at the University of Hong Kong jointly brought a study shows that interferon β-1b, lopinavir - ritonavir and ribavirin "triple therapy" effective and safe in the treatment of early COVID-19The report on May 9, published in the top international medical journal "The Lancet."https://doi.org/10.1016/S0140-6736(20)31042-4This is a multi-center study conducted in six public hospitals in Hong Kong, two open-label clinical, randomized testBetween 2020 and February 10 to March 20 period, the researchers recruited a total of 127 COVID-19 adult patients, male patients 68 (54%), female patients 59 (46%), with a median age of 52 years old (IQR 32-62), from symptom onset to admission median of 5 days (IQR 3-7), of which 51 (40%) patients with underlying diseasessubjects randomly assignedresearchers 86 patients included in the combined treatment group, 41 patients belonged to the remaining control groupJoint patients every 12 hours of oral 400 mg lopinavir, 100 mg ritonavir and 400 mg ribavirin, and optionally received subcutaneous injections every other day interferon β-1b (one to three); Control group received orally lopinavir / ritonavir therapyStudy duration of 14 daysshould be noted that, to avoid the proinflammatory effects of interferon-β-1b in the combined treatment group, 52 patients researchers only after the onset of symptoms admitted less than 7 days to take triple therapy, symptoms 34 seizures in patients from 7 days to 14 days of hospital admission were ritonavir / lopinavir and ribavirin combination therapytreatment results showed that patients receiving combined treatment of nasal swabs into the negative time is significantly shorter than the control group, the median time was 7 days (IQR 5-11), while the control group was 12 days ( IQR 8-15)By day 8, the majority of patients receiving triple therapy of all samples were negative RT-PCR samplesMeanwhile, joint clinical symptoms remission time is significantly shorter median time of 4 days (IQR 3-8), while the control group of 8 days (IQR 7-9) In addition, compared with the control group, patients in the combination group bit shorter hospital stay of 5.5 days (14.5 days vs 9.0 days) Data treatment groups were Further analysis showed that 76 patients in the onset of symptoms in less than seven days of hospitalization, 52 receiving triple therapy clinical and virological outcome of patients than the control group 24 patients; 7 days but 51 patients hospitalized in the onset of symptoms, compared with the control group, who did not receive injections of interferon β-1b of the combination group was not observed in better efficacy This shows that interferon β-1b is to get the key from the patient to shorten the duration of symptoms begin the first week of treatment course of treatment, there was no significant difference between two groups adverse events, the combination therapy group No serious adverse reactions conclusion, this study suggests that interferon β-1b, lopinavir / ritonavir and ribavirin triple antiviral therapy in viral shedding shortened, alleviating the symptoms of mild to moderate symptoms and promote COVID -19 patients discharged from hospital, the use of lopinavir alone than - ritonavir safer and more effective However, researchers suggested the need for further studies to examine the use of interferon-β-1b alone or in combination with other drugs for the treatment effect of COVID-19 a References: [1] Triplecombination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in thetreatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial < br /> [2] Interferonbeta-1b for COVID-19 editor: Squirtle Related tags: National , the new crown pneumonia , antiviral treatment 0 0
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.